GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » YoY EBITDA Growth

Sihuan Pharmaceutical Holdings Group (HKSE:00460) YoY EBITDA Growth : 105.80% (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Sihuan Pharmaceutical Holdings Group YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Sihuan Pharmaceutical Holdings Group's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 105.80%.

Sihuan Pharmaceutical Holdings Group's EBITDA per Share for the six months ended in Dec. 2023 was HK$0.01.

Sihuan Pharmaceutical Holdings Group YoY EBITDA Growth Historical Data

The historical data trend for Sihuan Pharmaceutical Holdings Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sihuan Pharmaceutical Holdings Group YoY EBITDA Growth Chart

Sihuan Pharmaceutical Holdings Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -187.10 154.32 -9.85 -254.62 121.20

Sihuan Pharmaceutical Holdings Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -110.53 -66.40 -2,700.00 -38.10 105.80

Sihuan Pharmaceutical Holdings Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Sihuan Pharmaceutical Holdings Group's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.039--0.184)/ | -0.184 |
=121.20 %

Sihuan Pharmaceutical Holdings Group's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(0.013--0.224)/ | -0.224 |
=105.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sihuan Pharmaceutical Holdings Group YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Sihuan Pharmaceutical Holdings Group's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sihuan Pharmaceutical Holdings Group Ltd (HKSE:00460) » Definitions » YoY EBITDA Growth
Comparable Companies
HKSE:01681 HKSE:01349 HKSE:02877 HKSE:06896 HKSE:03613 HKSE:02348 HKSE:01558 HKSE:01061 HKSE:02552 HKSE:02633 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
SHPHF:USA
Address
Zhubang 2000 Business Centre, 22nd Floor, Building 4, West Balizhuang, Chaoyang District, Beijing, CHN, 100025
Website
https://www.sihuanpharm.com
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Digestive System, Anti-Infective, metabolism, Respiratory, Neurology, and Others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others to provide non- or minimally invasive medical aesthetics comprehensive solutions; the innovative medicine and other medicine segments; and the generic medicine segment.
Executives
Che Fengsheng 2201 Interest of corporation controlled by you
Guo Weicheng 2201 Interest of corporation controlled by you
Meng Xianhui 2201 Interest of corporation controlled by you
Zhang Jionglong 2201 Interest of corporation controlled by you
Mingyao Capital Limited 2401 A concert party to an agreement to buy shares
Network Victory Limited 2401 A concert party to an agreement to buy shares
Proper Process International Limited 2401 A concert party to an agreement to buy shares
Successmax Global Holdings Limited 2101 Beneficial owner
Victory Faith International Limited 2401 A concert party to an agreement to buy shares
Ubs Tc (jersey) Ltd 2301 Trustee
Ubs Trustees (cayman) Ltd. 2301 Trustee
Smart Top Overseas Limited 2501 Other
Plenty Gold Enterprises Limited 2307 Founder of a discretionary trust who can infl

Sihuan Pharmaceutical Holdings Group (HKSE:00460) Headlines

No Headlines